| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 4244247 | Médecine Nucléaire | 2011 | 5 Pages |
Abstract
Normal prostate cells and prostate cancer cells produce prostate-specific antigen (PSA): thus, it is frequently increased in non-malignant conditions such as prostatitis and benign prostatic hyperplasia. Indeed, PSA is an excellent biomarker to monitor disease progression. The low diagnostic specificity of PSA leads to many false-positive and a large number of biopsies. These well-recognized limitations of PSA suggest that new prostate cancer biomarkers could play a useful role in reducing the number of unnecessary biopsies.
Related Topics
Health Sciences
Medicine and Dentistry
Radiology and Imaging
Authors
A.-S. Gauchez,